$747K
1 filing since 2025 · latest Equity filed
GelMEDIX is a preclinical ophthalmology biotech developing regenerative therapies to restore vision lost to degenerative retinal disease. Its core technology is a proprietary in situ forming, photo-crosslinked hydrogel that acts as an injectable scaffold, protecting cells during injection, localizing them at the target site, and providing a framework for tissue regeneration. The lead program, GMX-101, is a retinal pigment epithelial cell therapy for late-stage Geographic Atrophy. The company was founded out of academic collaboration between Reza Dana of Mass. Eye and Ear and Harvard Medical School and Nasim Annabi of UCLA, and is based in Cambridge, Massachusetts.
What sets it apart
An injectable hydrogel scaffold that protects transplanted cells during injection and holds them at the target site, addressing the poor cell survival and localization that limit conventional retinal cell therapy delivery. The same platform supports payloads from small molecules through cell and gene therapies.
A retinal pigment epithelial (RPE) cell therapy delivered in GelMEDIX's injectable hydrogel scaffold, in preclinical development for late-stage Geographic Atrophy, the leading cause of irreversible blindness in adults over 60.
